Economic success in the generic pharmaceutical industry depends on timing. Between 2026 and 2030, blockbuster drugs representing an estimated $236 […]

The 20-year patent term is a nominal legal baseline that rarely reflects the commercial reality of a pharmaceutical product. While

The Billion-Dollar Blind Spot in Pharmaceutical Strategy Every year, pharmaceutical executives sit in board meetings with revenue projections that quietly

Every major drug facing generic competition is a battlefield. The weapon of choice is not chemistry or clinical data—it is

Branded generics occupy a middle ground between expensive branded drugs and bare-bones unbranded generics. These products use off-patent active ingredients

The pharmaceutical industry has long been viewed through a binary lens. On one side, the high-stakes, high-margin world of patented

An investigative analysis of the business architecture behind pharma’s most durable profit model When Pfizer’s patent on atorvastatin expired in

The maturation of algorithmic discovery The pharmaceutical industry reached an inflection point in 2025 as artificial intelligence transitioned from a

The pharmaceutical industry is struggling with its own productivity. The cost of bringing a single new chemical entity to market